During the last session, Eliem Therapeutics Inc (NASDAQ:ELYM)’s traded shares were 1.11 million, with the beta value of the company hitting -0.33. At the end of the trading day, the stock’s price was $6.99, reflecting an intraday loss of -5.03% or -$0.37. The 52-week high for the ELYM share is $11.55, that puts it down -65.24 from that peak though still a striking 66.38% gain since the share price plummeted to a 52-week low of $2.35. The company’s market capitalization is $468.75M, and the average intraday trading volume over the past 10 days was 0.22 million shares, and the average trade volume was 204.21K shares over the past three months.
Eliem Therapeutics Inc (ELYM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. ELYM has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Eliem Therapeutics Inc (NASDAQ:ELYM) trade information
Eliem Therapeutics Inc (ELYM) registered a -5.03% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.03% in intraday trading to $6.99, hitting a weekly high. The stock’s 5-day price performance is 16.50%, and it has moved by -11.74% in 30 days. Based on these gigs, the overall price performance for the year is 156.99%. The short interest in Eliem Therapeutics Inc (NASDAQ:ELYM) is 1.07 million shares and it means that shorts have 4.43 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.72%.
ELYM Dividends
Eliem Therapeutics Inc is due to release its next quarterly earnings on 2023-May-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Eliem Therapeutics Inc (NASDAQ:ELYM)’s Major holders
Eliem Therapeutics Inc insiders own 10.38% of total outstanding shares while institutional holders control 77.67%, with the float percentage being 86.66%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 66.0 institutions own stock in it. As of 2024-06-30, the company held over 31.42 million shares (or 103.5246% of all shares), a total value of $223.39 million in shares.
The next largest institutional holding, with 3.9 million shares, is of DEEP TRACK CAPITAL, LP’s that is approximately 12.866% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $27.76 million.
